Our Pipeline
Accelerating the delivery of medicines to patients with unmet need
[image placeholder – do not delete]
We are a global company working to accelerate the development and commercialization of important new treatment options that have the potential to improve patient care and outcomes. The diverse development candidates in our pipeline have one thing in common – they are being developed to address conditions with significant unmet patient need. We have a team of patient-focused experts in drug development who recognize the critical importance of accelerating the development of our pipeline in order to bring new medicines to patients more quickly.
We are also leveraging our unparalleled DrugOME technology and Digital Innovation platform to develop potentially first- or –best-in-class therapies across multiple indications and to speed delivery of new medicines to patients who need new treatment options.
Myovant Development
Relugolix
Symptoms of Uterine Fibroids — Combination Therapy
Approved by the FDA
Advanced Prostate Cancer — Monotherapy
Approved by the FDA
Symptoms of Endometriosis — Combination Therapy
Spirit Study — Phase 3
MVT-602
Female Infertility as Part of Assisted Reproduction
Phase 2
Japanese Development
Relugolix
Symptoms of Uterine Fibroids — Monotherapy
Approved
Symptoms of Endometriosis — Monotherapy
Phase 2
Vibegron
β3-adrenergic Agonist
EMPOWUR Overactive Bladder
Approved by the FDA
Overactive Bladder in Men with BPH
Courage Study Phase 3
Irritable Bowel Syndrome Associated Pain
Phase 2
URO-902
Gene Therapy for Overactive Bladder
Phase 2
Overactive Bladder
Phase 1
T-cell Platform
RVT-802
Congenital Athymia
BLA has been accepted by the FDA
Rodatristat Ethyl
Pulminary Arterial Hypertension (PAH)
Phase 2
Idiopathic Pulmonary Fibrosis (IPF)
Phase 1
ALTA-2530
Bronchiolitis Obliterans Syndrome
IND Enabling
SPIRO-2101
rAAV
Cystic Fibrosis
Preclinical
SPIRO-2102
LVV
Cystic Fibrosis
Preclinical
SPIRO-2110
rAAV
Cystic Fibrosis
Research
*Sumitovant is the majority shareholder of Myovant